Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Edurant
EDURANT 25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-213955 · Präparat HOS-155234
8
Cimetidine Not studied.
Nizatidine
Ranitidine (reduced absorption due to gastric
pH increase)
ANTACIDS
Antacids (e.g., Not studied. Significant decreases The combination of rilpivirine and
aluminium or magnesium in rilpivirine plasma concentrations antacids should be used with particular
hydroxide, calcium are expected. caution. Antacids should only be
carbonate) administered either at least 2 hours
(reduced absorption due to gastric before or at least 4 hours after
pH increase) rilpivirine.
NARCOTIC ANALGESICS
Methadone* R(-) methadone AUC ↓ 16% No dose adjustments are required
60-100 mg once daily, R(-) methadone Cmin ↓ 22% when initiating co-administration of
individualised dose R(-) methadone Cmax ↓ 14% methadone with rilpivirine. However,
rilpivirine AUC ↔* clinical monitoring is recommended as
rilpivirine Cmin ↔* methadone maintenance therapy may
rilpivirine Cmax ↔* need to be adjusted in some patients.
* based on historic controls
ANTIARRHYTHMICS
Digoxin* digoxin AUC ↔ No dose adjustment is required.
digoxin Cmin NA
digoxin Cmax ↔
ANTICOAGULANTS
Dabigatran etexilate Not studied. A risk for increases in The combination of rilpivirine and
dabigatran plasma concentrations dabigatran etexilate should be used
cannot be excluded. with caution.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nizatidine (HOS-138496) methadone (HOS-086198) cimetidine (HOS-085835) digoxin (HOS-086172) dabigatran (HOS-112096) calcium (HOS-085615) ranitidine (HOS-085660) magnesium (HOS-085165) dabigatran etexilate (HOS-086233)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage a82647616d2369ed93f5c1c0ca58dde62668e3f570c10a0d9aee6e832fcc541a · Zeichen 14265–16215 im Abschnitt
Wechselwirkungen · Edurant
EDURANT 2.5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 31
HOS-214008 · Präparat HOS-155234
(reduced absorption due to gastric
pH increase)
Lansoprazole Not studied. Significant decreases
Rabeprazole in rilpivirine plasma concentrations
Pantoprazole are expected.
Esomeprazole
(reduced absorption due to gastric
pH increase)
H2-RECEPTOR ANTAGONISTS
Famotidine*# rilpivirine AUC ↓ 9% The combination of rilpivirine and
40 mg single dose taken rilpivirine Cmin NA H2-receptor antagonists should be used
12 hours before rilpivirine Cmax ↔ with particular caution. Only
rilpivirine H2-receptor antagonists that can be
Famotidine*# rilpivirine AUC ↓ 76% dosed once daily should be used.
40 mg single dose taken rilpivirine Cmin NA A strict dosing schedule, with intake of
2 hours before rilpivirine rilpivirine Cmax ↓ 85% H2-receptor antagonists at least
12 hours before or at least 4 hours
(reduced absorption due to gastric after rilpivirine should be used.
pH increase)
Famotidine*# rilpivirine AUC ↑ 13%
40 mg single dose taken rilpivirine Cmin NA
4 hours after rilpivirine rilpivirine Cmax ↑ 21%
Cimetidine Not studied.
Nizatidine
Ranitidine (reduced absorption due to gastric
pH increase)
ANTACIDS
Antacids (e.g., Not studied. Significant decreases The combination of rilpivirine and
aluminium or magnesium in rilpivirine plasma concentrations antacids should be used with particular
hydroxide, calcium are expected. caution. Antacids should only be
carbonate) administered either at least 2 hours
(reduced absorption due to gastric before or at least 4 hours after
pH increase) rilpivirine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) nizatidine (HOS-138496) rabeprazole (HOS-114843) esomeprazole (HOS-087944) cimetidine (HOS-085835) pantoprazole (HOS-085167) famotidine (HOS-112087) calcium (HOS-085615) ranitidine (HOS-085660) magnesium (HOS-085165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage 127a046a3ba0f0f2919bad57eab9493f739a4627df3219ad6f8640932758cd01 · Zeichen 11316–13658 im Abschnitt
Wechselwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 15–16
HOS-138495 · Präparat HOS-098200
15
OTHER LIPID MODIFYING AGENTS
Lomitapide Based on theoretical Co-administration is
considerations, Symtuza is contraindicated (see section 4.3).
expected to increase the exposure
of lomitapide when co-
administered.
(CYP3A inhibition)
H2-RECEPTOR ANTAGONISTS
Cimetidine Based on theoretical Symtuza can be co-administered
Famotidine considerations, no mechanistic with H2-receptor antagonists
Nizatidine interaction is expected. without dose adjustments.
Ranitidine
IMMUNOSUPPRESSANTS
Ciclosporin Based on theoretical considerations Concentration monitoring of the
Sirolimus DRV/COBI is expected to increase immunosuppressive agent must
Tacrolimus these immunosuppressant plasma be done when co-administration
concentrations. with Symtuza occurs.
(CYP3A inhibition)
Co-administration of ciclosporin is
expected to increase plasma
concentrations of tenofovir
alafenamide.
(P-gp inhibition) Concomitant use of everolimus
Everolimus and Symtuza is not
recommended.
INHALED BETA AGONISTS
Salmeterol Based on theoretical considerations
Concomitant use of salmeterol
DRV/COBI is expected to increase
and Symtuza is not
salmeterol plasma concentrations.
recommended. The combination
(CYP3A inhibition) may result in increased risk of
cardiovascular adverse events
with salmeterol, including QT
prolongation, palpitations and
sinus tachycardia.
NARCOTIC ANALGESICS/TREATMENT OF OPIOID DEPENDENCE
Buprenorphine/naloxone Based on theoretical considerations Dose adjustment for
DRV/COBI may increase buprenorphine may not be
buprenorphine and/or necessary when co-administered
norbuprenorphine plasma with Symtuza, but a careful
concentrations. clinical monitoring for signs of
opiate toxicity is recommended.
Methadone Based on theoretical considerations No adjustment of methadone dose
DRV/COBI may increase is expected when initiating
methadone plasma concentrations. co-administration with Symtuza.
Clinical monitoring is
With ritonavir-boosted darunavir, a recommended, as maintenance
small decrease in methadone therapy may need to be adjusted
plasma concentrations was in some patients.
observed. Consult the Summary of
Product Characteristics for
darunavir for further details.
Fentanyl Based on theoretical considerations Clinical monitoring is
Oxycodone DRV/COBI may increase plasma recommended when
Tramadol concentrations of these analgesics. co-administering Symtuza with
(CYP2D6 and/or CYP3A these analgesics.
inhibition)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) nizatidine (HOS-138496) methadone (HOS-086198) cimetidine (HOS-085835) lomitapide (HOS-086160) oxycodone (HOS-109487) famotidine (HOS-112087) buprenorphine (HOS-086193) salmeterol (HOS-086285) tacrolimus (HOS-085202) ranitidine (HOS-085660) everolimus (HOS-086310) naloxone (HOS-109490) sirolimus (HOS-085172) fentanyl (HOS-086196) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage 65d1745e79031f8ffd732f400ccf71034e05cacd98fcfff4372c4246da9af398 · Zeichen 33001–37311 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-138690 · Präparat HOS-098240
Lansoprazole Rilpivirine
Rabeprazole Not studied. Significant
Pantoprazole decreases in rilpivirine
Esomeprazole/ plasma concentrations are
Rilpivirine expected
(reduced absorption due to
gastric pH increase).
H2-recepter antagonists
Famotidine Dolutegravir The combination of dolutegravir/rilpivirine and
Cimetidine (Not studied) H2-receptor antagonists should be used with
Nizatidine particular caution. Only H2-receptor antagonists
Ranitidine/ that can be dosed once daily should be used.
Dolutegravir
H2-receptor antagonists should be taken well
Famotidine/ Rilpivirine separated in time from the administration of
Rilpivirine1,2 AUC ↓ 9% dolutegravir/rilpivirine (minimum 4 hours after or
40 mg single dose Cmin NA 12 hours before)
taken 12 hours before Cmax ↔
rilpivirine
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) nizatidine (HOS-138496) rabeprazole (HOS-114843) esomeprazole (HOS-087944) cimetidine (HOS-085835) pantoprazole (HOS-085167) famotidine (HOS-112087) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage ea9028ca3d0fa3d4c503c1b3af0236bf88a7f581c3738dab63a63d57e45bc310 · Zeichen 15199–16371 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11
HOS-138693 · Präparat HOS-098240
Cimetidine Rilpivirine
Nizatidine Not studied. Significant
Ranitidine/ decreases in rilpivirine
Rilpivirine plasma concentrations are
expected (reduced
absorption due to gastric pH
increase).
Antacids and supplements
Antacids (e.g., Dolutegravir The combination of dolutegravir/rilpivirine and
aluminium AUC 74% antacids should be used with particular caution.
magnesium hydroxide, Cmax 72% Antacids should be taken well separated in time
and/or calcium C24 74% from the administration of dolutegravir/rilpivirine
carbonate)/ (Complex binding to (minimum 6 hours before or 4 hours after).
Dolutegravir1 polyvalent ions).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nizatidine (HOS-138496) cimetidine (HOS-085835) magnesium hydroxide (HOS-088789) calcium (HOS-085615) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage 23216f913fdd6876d7efb0a97aabf378224d693f6693b0f6d9a74ec1ef13db94 · Zeichen 16767–17651 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.